Immunic, Inc. (IMUX): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMUX Stock Price Chart Interactive Chart >
IMUX Price/Volume Stats
| Current price | $6.11 | 52-week high | $15.12 |
| Prev. close | $6.08 | 52-week low | $4.96 |
| Day low | $5.97 | Volume | 156,000 |
| Day high | $6.35 | Avg. volume | 289,253 |
| 50-day MA | $8.57 | Dividend yield | N/A |
| 200-day MA | $9.65 | Market Cap | 186.60M |
Immunic, Inc. (IMUX) Company Bio
Immunic Inc. (formerly Vital Therapies) is a biotherapeutic company developing a cell-based therapy targeting the treatment of liver failure. The company was founded in 2003 and is based in San Diego, California.
Latest IMUX News From Around the Web
Below are the latest news stories about Immunic Inc that investors may wish to consider to help them evaluate IMUX as an investment opportunity.
Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent ActivityImmunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent activity. |
Immunic FY 2021 Earnings PreviewImmunic (NASDAQ:IMUX) is scheduled to announce FY earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$3.73... |
Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative ColitisImmunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that Evelyn Peelen, Ph.D., Senior Manager Translational Pharmacology at Immunic, will present preclinical data on the potent anti-inflammatory activity of vidofludimus calcium (IMU-838), the company's selective oral DHODH inhibitor, at the 17th Congress of European Crohn's and Colitis |
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate UpdateImmunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2021, including a corporate update, on Thursday, February 24, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. |
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
IMUX Price Returns
| 1-mo | -16.19% |
| 3-mo | -42.84% |
| 6-mo | -26.56% |
| 1-year | -54.77% |
| 3-year | -34.86% |
| 5-year | -94.64% |
| YTD | -36.15% |
| 2021 | -37.41% |
| 2020 | 57.63% |
| 2019 | 27.63% |
| 2018 | -96.81% |
| 2017 | 36.78% |
Loading social stream, please wait...